We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: OB/GYN & Women's Health

ChatGPT-4o versus Gynecologic Oncologists in Endometrial Cancer Patient Communication: A Prospective Comparative Study

MedXY Editorial Team•Oct 5, 2025•OB/GYN & Women's Health
ChatGPT-4oEndometrial CancerPatient Communication

Study Background and Disease Burden

Endometrial cancer represents one of the most common gynecologic malignancies worldwide, with increasing incidence attributed to aging populations and rising obesity rates. Effective patient communication regarding risk factors, preventive strategies, diagnostic procedures, and treatment options is essential to optimize patient outcomes and quality of life. However, time constraints in clinical encounters and variability in communication skills may limit thorough patient education. This unmet need presents an opportunity to explore artificial intelligence (AI) applications like ChatGPT-4o to supplement clinical interactions and improve patient understanding and support. By examining AI performance against specialized gynecologic oncologists in addressing patient inquiries about endometrial cancer, this study provides timely insights into AI’s role within the evolving oncology care landscape.

Study Design

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Impact of Mutated p53 on Type I Interferon Pathway Expression in Endometrial Cancer: Immune Modulatory InsightsThis study reveals distinct alterations in the type I interferon pathway expression and signaling linked to mutated p53 subtypes in endometrial cancer, highlighting differing immune microenvironments that impact prognosis and therapeutic coSep 12, 2026High Venous Thromboembolism Incidence in Endometrial Cancer Patients Undergoing Chemotherapy: Implications for Risk Stratification and ProphylaxisOver 25% of endometrial cancer patients receiving chemotherapy develop venous thromboembolism, with advanced cancer stage as the key risk factor, highlighting the need for tailored risk assessment and preventive strategies.Sep 1, 2026Clinical Impact of Sentinel Lymph Node Biopsy in Atypical Endometrial Hyperplasia: Insights from a Multicenter Cohort StudySentinel lymph node biopsy in atypical endometrial hyperplasia patients identifies occult cancers and refines adjuvant treatment strategies, supporting its safe and feasible use for better risk stratification.Aug 27, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data
This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.
Aug 22, 2026
Metabolic and Bariatric Surgery in the Care of Endometrial Intraepithelial Neoplasia and Endometrial Cancer: Key Guidance from the SGO–SAGES Joint StatementA clear, evidence-based summary of the 2026 SGO–SAGES clinical practice statement recommending integration of metabolic and bariatric surgery into multidisciplinary care for women with EIN and endometrial cancer.Aug 12, 2026
MLH1 Promoter Hypermethylation Does Not Impact Survival Outcomes in dMMR Endometrial Cancer Treated with Immune Checkpoint InhibitorsThis study analyzes real-world data showing that MLH1 promoter hypermethylation and Lynch syndrome-associated genetic mutations confer similar response rates and survival outcomes in mismatch repair deficient endometrial cancer treated withAug 18, 2026